Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry-Reference-Cited by-同舟云学术

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

Published:2017-02 Issue:2 Volume:137 Page:313-321
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Dávila-Seijo Paula,Dauden Esteban,Descalzo M.A.,Carretero Gregorio,Carrascosa José-Manuel,Vanaclocha Francisco,Gómez-García Francisco-José,De la Cueva-Dobao Pablo,Herrera-Ceballos Enrique,Belinchón Isabel,López-Estebaranz José-Luis,Alsina Merce,Sánchez-Carazo José-Luis,Ferrán Marta,Torrado Rosa,Ferrandiz Carlos,Rivera Raquel,Llamas Mar,Jiménez-Puya Rafael,García-Doval Ignacio^ORCID,Pérez Zafrilla Beatriz,Muñoz-Santos Carlos,Mendiola-Fernández Victoria,Sánchez Roldán Cristina,Ruiz-Genao Diana,Echeverría Begoña,Galiano Mejías Sagrario

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference30 articles.

1. Risk of infections associated with biological treatment in inflammatory bowel disease;Andersen;World J Gastroenterol,2014

2. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation;Armstrong;JAMA Dermatol,2015

3. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry;Atzeni;Autoimmun Rev,2012

4. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

5. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry;Carrascosa;J Eur Acad Dermatol Venereol,2013

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial;Nature Medicine;2024-07-30

2. Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest;Journal of Clinical Medicine;2024-06-26

3. Macromolecular Biomaterials Endowed Strategies for Synergistic Treatment of Psoriasis: Recent Advancements and Future Prospects;Journal of Macromolecular Science, Part B;2024-06-03

4. Systemic therapy for psoriasis and the risk of cutaneous infections;The Journal of Dermatology;2024-04-25

5. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis;Frontiers in Immunology;2023-11-29